Evidence map›Paper›PMID 38665834›Full record

ArticleRSC medicinal chemistry2024

Design, quality and validation of the EU-OPENSCREEN fragment library poised to a high-throughput screening collection.

Xavier Jalencas, Hannes Berg, Ludvik Olai Espeland, Sridhar Sreeramulu, Franziska Kinnen, Christian Richter, Charis Georgiou, Vladyslav Yadrykhinsky, Edgar Specker, Kristaps Jaudzems and 8 more

Open access · hybridAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. ECBD: European chemical biology database.Nucleic acids research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 6 countries.

Xavier JalencasResearch Group on Systems Pharmacology, Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical Research Institute Parc de Recerca Biomèdica (PRBB), Doctor Aiguader 88 08003 Barcelona Spain jmestres@imim.es.ORCID https://orcid.org/0000-0003-3818-0855
Hannes BergCenter for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry Max-von-Laue-Str. 7 60438 Frankfurt/M Germany schwalbe@nmr.uni-frankfurt.de.ORCID https://orcid.org/0000-0002-2060-4296
Ludvik Olai EspelandDepartment of Biomedicine, University of Bergen Jonas Lies Vei 91 5020 Bergen Norway.ORCID https://orcid.org/0000-0002-2916-9315
Sridhar SreeramuluCenter for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry Max-von-Laue-Str. 7 60438 Frankfurt/M Germany schwalbe@nmr.uni-frankfurt.de.ORCID https://orcid.org/0000-0003-4509-4568
Franziska KinnenCenter for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry Max-von-Laue-Str. 7 60438 Frankfurt/M Germany schwalbe@nmr.uni-frankfurt.de.
Christian RichterCenter for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry Max-von-Laue-Str. 7 60438 Frankfurt/M Germany schwalbe@nmr.uni-frankfurt.de.ORCID https://orcid.org/0000-0002-5420-2826
Charis GeorgiouDepartment of Biomedicine, University of Bergen Jonas Lies Vei 91 5020 Bergen Norway.ORCID https://orcid.org/0000-0002-1638-1245
Vladyslav YadrykhinskyDepartment of Biomedicine, University of Bergen Jonas Lies Vei 91 5020 Bergen Norway.ORCID https://orcid.org/0000-0003-4224-6765
Edgar SpeckerEU-OPENSCREEN ERIC Robert-Rössle Straße 10 13125 Berlin Germany.
Kristaps JaudzemsLatvian Institute of Organic Synthesis Aizkraules 21 Riga LV-1006 Latvia aigars@osi.lv.ORCID https://orcid.org/0000-0003-3922-2447
Tanja MiletićEU-OPENSCREEN ERIC Robert-Rössle Straße 10 13125 Berlin Germany.ORCID https://orcid.org/0000-0003-3893-7045
Robert HarmelEU-OPENSCREEN ERIC Robert-Rössle Straße 10 13125 Berlin Germany.ORCID https://orcid.org/0000-0003-4413-7730
Phil GribbonFraunhofer Institute for Translational Medicine and Pharmacology (ITMP) Schnackenburgallee 114 22525 Hamburg Germany andrea.zaliani@itmp.fraunhofer.de.ORCID https://orcid.org/0000-0001-7655-2459
Harald SchwalbeCenter for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry Max-von-Laue-Str. 7 60438 Frankfurt/M Germany schwalbe@nmr.uni-frankfurt.de.ORCID https://orcid.org/0000-0001-5693-7909
Ruth BrenkDepartment of Biomedicine, University of Bergen Jonas Lies Vei 91 5020 Bergen Norway.ORCID https://orcid.org/0000-0002-6204-5488
Aigars JirgensonsLatvian Institute of Organic Synthesis Aizkraules 21 Riga LV-1006 Latvia aigars@osi.lv.ORCID https://orcid.org/0000-0002-8937-8792
Andrea ZalianiFraunhofer Institute for Translational Medicine and Pharmacology (ITMP) Schnackenburgallee 114 22525 Hamburg Germany andrea.zaliani@itmp.fraunhofer.de.ORCID https://orcid.org/0000-0002-1740-8390
Jordi MestresResearch Group on Systems Pharmacology, Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical Research Institute Parc de Recerca Biomèdica (PRBB), Doctor Aiguader 88 08003 Barcelona Spain jmestres@imim.es.ORCID https://orcid.org/0000-0002-5202-4501
Goethe University Frankfurt · DELatvijas Organiskās Sintēzes Institūts · LVMerck (Germany) · DEUniversity of Bergen · NOMunicipal Institute for Medical Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EU-OPENSCREEN (EU-OS) European Research Infrastructure Consortium (ERIC) is a multinational, not-for-profit initiative that integrates high-capacity screening platforms and chemistry groups across Europe to facilitate research in chemical biology and early drug discovery. Over the years, the EU-OS has assembled a high-throughput screening compound collection, the European Chemical Biology Library (ECBL), that contains approximately 100 000 commercially available small molecules and a growing number of thousands of academic compounds crowdsourced through our network of European and non-European chemists. As an extension of the ECBL, here we describe the computational design, quality control and use case screenings of the European Fragment Screening Library (EFSL) composed of 1056 mini and small chemical fragments selected from a substructure analysis of the ECBL. Access to the EFSL is open to researchers from both academia and industry. Using EFSL, eight fragment screening campaigns using different structural and biophysical methods have successfully identified fragment hits in the last two years. As one of the highlighted projects for antibiotics, we describe the screening by Bio-Layer Interferometry (BLI) of the EFSL, the identification of a 35 μM fragment hit targeting the beta-ketoacyl-ACP synthase 2 (FabF), its binding confirmation to the protein by X-ray crystallography (PDB 8PJ0), its subsequent rapid exploration of its surrounding chemical space through hit-picking of ECBL compounds that contain the fragment hit as a core substructure, and the final binding confirmation of two follow-up hits by X-ray crystallography (PDB 8R0I and 8R1V).

Identifiers

PMID38665834
PMCPMC11042166
OpenAlexW4391758524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.